Nirav N. Shah, MD

NEW ORLEANS — Patients with newly diagnosed mantle cell lymphoma who received ibrutinib with a standard-of-care regimen had higher failure-free survival rates than those who received standard-of-care treatment alone.

Second-line therapy with axicabtagene ciloleucel conferred a fourfold increase in EFS compared with standard-of-care treatment for diffuse large B-cell lymphoma, according to results of a randomized phase 3 study.

The chimeric antigen receptor T-cell therapies axicabtagene ciloleucel and tisagenlecleucel may meet a cost-effectiveness threshold of less than $150,000 per quality-adjusted life-year gained for adults with diffuse large B-cell lymphoma, according to results of a study published in Journal of Clinical Oncology.